Use of survivin antagonists in polyomavirus-related disease
View Patent ↗A method of treating a polyomavirus (+) cancer in which survivin is upregulated in a patient is provided, comprising administering to the patient a therapeutically effective amount of a composition that downregulates survivin expression or function in cells of the polyomavirus (+) cancer. A method of reducing growth of polyomavirus (+) cancer cells in which survivin is up-regulated is provided, comprising contacting the cells with an amount of a composition that downregulates survivin expression or function effective to reduce growth of the cells. Also provided is sepantronium salt, for use in treating a polyomavirus (+) cancer in which survivin is up-regulated.
1. A method of treating a polyomavirus (+) cancer in which survivin is upregulated in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising a compound having the structure:
wherein X is a pharmaceutically acceptable counterion.
2. The method of claim 1 , in which the polyomavirus (+) cancer is a Merkel cell polyomavirus (+) Merkel cell carcinoma and the composition comprises YM155.
3. The method of claim 1 , wherein the polyomavirus (+) cancer is a polyomavirus (+) Merkel cell carcinoma.
4. The method of claim 1 , wherein the polyomavirus (+) cancer is caused by JC virus, BK virus, Karolinska institute virus, or Washington University virus.
5. The method of claim 1 , wherein the compound is YM155.
6. The method of claim 1 , wherein the composition comprises one or more additional active agents.
7. The method of claim 6 , in which the one or more additional active agent is one or more of an anticancer chemotherapeutic agent, an antibiotic, a protein-based therapeutic, an antibody or fragment thereof, an antiemetic, a cell-based therapeutic, a cell-based immunotherapeutic, or a vector comprising a gene for producing a therapeutic or immunotherapeutic composition.
8. The method of claim 1 , in which the composition comprises an interfering nucleic acid.
9. The method of claim 8 , in which the interfering nucleic acid targets one of survivin, ILF3, p54nrb or polyomavirus T antigen.
10. The method of claim 1 , comprising administering the composition to the patient in an amount of from about 2 mg/kg per day to about 10 mg/kg per day.
11. The method of claim 10 , wherein the composition is administered on from one to seven days weekly.
12. The method of claim 10 , comprising administering YM155 to the patient in an amount of about 2 mg/kg about five times weekly to the patient.
13. A method of reducing growth of polyomavirus (+) cancer cells in which survivin is up-regulated, comprising contacting the cells with-a composition comprising a compound having the structure:
wherein X is a pharmaceutically acceptable counterion, in an amount effective to reduce growth of the cells.
14. The method of claim 13 , in which the composition is YM155.
15. The method of claim 14 , in which the cells are in vitro.